Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer is a highly respected drug company facing normal industry headwinds.

Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer is a highly respected drug company facing normal industry headwinds.

Heres How Pfizers Oncology Growth Story Looks Ahead of Q2 Results

PFEs oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

The pharma giants yield of around 7.1% is more than six times the S&P 500 average.

CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics

NASDAQ: LABTDavid Bautz, PhD: Welcome to our next episode in our CEO Chat series. My name is David Bautz. Im a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics (NASDAQ: LABT). Lakewood-Amedex is developing the Bisphosphocin® class of antimicrobials to address unmet needs in the treatment of acute and chronic infectious diseases. We recently initiated coverage of Lakewood-Amedex with a $12 valuation. He...

Pfizer Aktie: Droht jetzt neuer Gegenwind?

Charlotte (www.aktiencheck.de) - Pfizer-Aktienanalyse der Bank of America (BofA):BofA habe das Kursziel für die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) von 27 auf 26 USD gesenkt und das "neutral"-Rating bestätigt. Nach Einschätzung der Analysten dürften die Ergebnisse für das zweite Quartal zeigen, dass Pharmakonzerne mit hochwertigen Medikamentenportfolios und nachhaltigen Wachstumstreibern weiterhin eine stärkere Entwicklung aufweisen wür...

FDA Expands MRK & PFEs Keytruda-Padcev Combo Use in Bladder Cancer

Mercks Keytruda in combination with Pfizers Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

Pfizer: The AI Hedge That Pays You To Stay Defensive

Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. Learn why PFE stock is a strong buy.

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pfizer Sector Perform

NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Pfizer mit einem Kursziel von 25 US-Dollar auf "Sector Perform" belassen. Seine Umsatzschätzung entspreche dem Konsens, schrieb Trung Huynh am Freitag in seinem Ausblick auf ...

JPMorgan resets LLY stock target on drug demand

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well.  On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

Opinion: Pfizers Dividend Is Riskier Than You Might Think

A 7% dividend yield will grab your attention, but be sure to read the fine print.

Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Pfizer (PFE) Stock Sinks As Market Gains: Heres Why

Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior days close.

Jefferies belässt Pfizer auf Buy - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Pfizer mit einem Kursziel von 34 US-Dollar auf "Buy" belassen. Mit Blick auf Vorab-Aussagen des Pharmakonzerns zu den anstehenden Quartalszahlen hob Akash Tewari in einem am Freitag vorliegenden Ausblick den Einfluss von Sondereffekten auf die Produktdynamik hervor. [mehr]

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported.  Lawmakers want each company to explain ...

Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock

It could prove to be a case of better later than never for the healthcare giant.

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

2026 Mid-Year Outlook: Big Market Risks, AI And Memory Mania Concerns, And My Top Bargain Stock Picks

Broad market bearishness prompts defensive buys in oversold defense stocks, high-yield Pfizer, and cash reserves. Read more here.

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.

Nike names former Pfizer CFO David Denton as finance chief

Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective...

Pfizer Aktie: Pipelineerfolge dringend notwendig

Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse der Raiffeisen Bank International AG:Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) unter die Lupe. [mehr]

LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?

Lillys GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.

BMO reiterates Pfizer stock Outperform on pipeline strength

BMO reiterates Pfizer stock Outperform on pipeline strength

Pfizer Neutral

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Pfizer auf "Neutral" mit einem Kursziel von 27 US-Dollar belassen. Die Be6A-Lungenkrebsstudie (NSLC) mit Sigvotatug Vedotin habe ihren primären Endpunkt beim Gesamtüberleben verfehlt, schrieb ...

Pfizer Isnt Expecting to Make Any Big Acquisition in the Next Couple of Years, but Its Planning to Do This Instead

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.